Journal of International Psychiatry

[Abstract] Objective: to analyze the efficacy and safety of aripiprazole in the treatment of refractory Sch. Methods: 76 patients with refractory Sch in our hospital from October 2019 to October 2020 were selected and divided into two groups according to "different treatment methods". 38 patients in the reference group were treated with olanzapine, while 38 patients in the experimental group were treated with aripiprazole on the basis of the reference group. The clinical efficacy, PANSS score, blood lipid index and total incidence of adverse reactions were compared between the two groups. Results: the clinical total effective rate of the experimental group (94.74%) was higher than that of the reference group (68.42%). The PANSS score, TG and TC of the experimental group were lower than those of the reference group after treatment, and the differences were statistically significant (P < 0.05). The total incidence of adverse reactions in the experimental group (5.26%) was higher than that in the control group (10.53%), P > 0.05. Conclusion: aripiprazole can effectively improve the mental symptoms of patients with refractory Sch, has little effect on blood lipid, and has low incidence of adverse reactions and high safety.

[Key words] aripiprazole; Refractory schizophrenia; Clinical effect; Adverse reactions